ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,691 | -30.6% | 917 | -10.2% | 0.00% | 0.0% |
| Q2 2023 | $47,099 | +64.0% | 1,021 | +42.6% | 0.00% | 0.0% |
| Q1 2023 | $28,712 | -57.6% | 716 | -51.0% | 0.00% | -50.0% |
| Q4 2022 | $67,734 | +170.9% | 1,462 | +143.7% | 0.00% | +100.0% |
| Q3 2022 | $25,000 | +78.6% | 600 | +151.0% | 0.00% | – |
| Q2 2022 | $14,000 | +40.0% | 239 | +69.5% | 0.00% | – |
| Q1 2022 | $10,000 | +25.0% | 141 | +50.0% | 0.00% | – |
| Q4 2021 | $8,000 | +300.0% | 94 | +248.1% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 27 | +350.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 6 | -64.7% | 0.00% | – |
| Q1 2021 | $2,000 | -33.3% | 17 | -22.7% | 0.00% | – |
| Q4 2020 | $3,000 | – | 22 | +266.7% | 0.00% | – |
| Q3 2020 | $0 | – | 6 | +500.0% | 0.00% | – |
| Q3 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2018 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |